Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Trial Profile

A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs LIK 066 (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Aug 2018 Planned End Date changed from 26 Sep 2019 to 1 Oct 2019.
    • 20 Aug 2018 Planned primary completion date changed from 26 Sep 2019 to 3 Sep 2019.
    • 13 Jun 2018 Planned primary completion date changed from 13 Apr 2019 to 26 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top